Innate Pharma SA (IPHA) Form 6-K — Aug 10, 2026
Innate Pharma has entered a strategic partnership licensing lacutamab, its anti-KIR3DL2 antibody for T-cell lymphoma, to Sobi, which receives exclusive global commercialization rights upon potential accelerated approval. Sobi will pay USD 75 million upfront on closing, with Innate eligible for up to USD 40 million in near-term Sézary syndrome milestones, up to USD 465 million tied to Sobi's option for full development rights and later milestones, plus tiered double-digit royalties on net sales.
Key figures
- Deal Value Usd
- Up to USD 580 million total potential (USD 75 million upfront + up to USD 40 million near-term milestones + up to USD 465 million option and later milestones)
- Royalty terms
- tiered double-digit royalties on net sales
- Cbo effective date
- September 1, 2026
- Cash runway extended to
- Q3 2027
- Upfront payment usd million
- 75
- Near term milestones usd million
- 40
- Option and milestone payments usd million
- 465
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.